Oncgnostics, a Jena, Germany-based diagnostic company, received a seven digit euro investment from Grande Bio-tech Co.
The company intends to use the funds to expand the distribution of its tests developed in the ASEAN countries.
Led by Dr. Martina Schmitz, CEO and Scientific Director, Oncgnostics has developed Gyntect for the detection of cervical cancer. Gyntect is a swab test that determines within a few hours whether there is a precancerous condition or a tumor on the cervix.
Since 2022, this test has also been distributed and utilized in collaboration with a local partner in China. The goal now is to expand the distribution of tests developed by Oncgnostics in the ASEAN countries.
FinSMEs
11/09/2023